Investigating the impact of COVID-19 lockdown on adults with a recent history of recurrent major depressive disorder: a multi-Centre study using remote measurement technology

on behalf of the RADAR-CNS consortium; Daniel Leightley; Grace Lavelle; Katie M. White; Shaoxiong Sun; Faith Matcham; Alina Ivan; Carolin Oetzmann; Brenda W.J.H. Penninx; Femke Lamers; Sara Siddi; Josep Mario Haro; Inez Myin-Germeys; Stuart Bruce; Raluca Nica; Alice Wickersham; Peter Annas; David C. Mohr; Sara Simblett; Til Wykes; Nicholas Cummins; Amos Akinola Folarin; Pauline Conde; Yatharth Ranjan; Richard J.B. Dobson; Viabhav A. Narayan; Mathew Hotopf

doi:10.1186/s12888-021-03434-5

Investigating the impact of COVID-19 lockdown on adults with a recent history of recurrent major depressive disorder: a multi-Centre study using remote measurement technology

on behalf of the RADAR-CNS consortium, Daniel Leightley^*, Grace Lavelle, Katie M. White, Shaoxiong Sun, Faith Matcham, Alina Ivan, Carolin Oetzmann, Brenda W.J.H. Penninx, Femke Lamers, Sara Siddi, Josep Mario Haro, Inez Myin-Germeys, Stuart Bruce, Raluca Nica, Alice Wickersham, Peter Annas, David C. Mohr, Sara Simblett, Til WykesNicholas Cummins, Amos Akinola Folarin, Pauline Conde, Yatharth Ranjan, Richard J.B. Dobson, Viabhav A. Narayan, Mathew Hotopf

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

Background: The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes a clinical illness Covid-19, has had a major impact on mental health globally. Those diagnosed with major depressive disorder (MDD) may be negatively impacted by the global pandemic due to social isolation, feelings of loneliness or lack of access to care. This study seeks to assess the impact of the 1st lockdown – pre-, during and post – in adults with a recent history of MDD across multiple centres. Methods: This study is a secondary analysis of an on-going cohort study, RADAR-MDD project, a multi-centre study examining the use of remote measurement technology (RMT) in monitoring MDD. Self-reported questionnaire and passive data streams were analysed from participants who had joined the project prior to 1st December 2019 and had completed Patient Health and Self-esteem Questionnaires during the pandemic (n = 252). We used mixed models for repeated measures to estimate trajectories of depressive symptoms, self-esteem, and sleep duration. Results: In our sample of 252 participants, 48% (n = 121) had clinically relevant depressive symptoms shortly before the pandemic. For the sample as a whole, we found no evidence that depressive symptoms or self-esteem changed between pre-, during- and post-lockdown. However, we found evidence that mean sleep duration (in minutes) decreased significantly between during- and post- lockdown (− 12.16; 95% CI − 18.39 to − 5.92; p < 0.001). We also found that those experiencing clinically relevant depressive symptoms shortly before the pandemic showed a decrease in depressive symptoms, self-esteem and sleep duration between pre- and during- lockdown (interaction p = 0.047, p = 0.045 and p < 0.001, respectively) as compared to those who were not. Conclusions: We identified changes in depressive symptoms and sleep duration over the course of lockdown, some of which varied according to whether participants were experiencing clinically relevant depressive symptoms shortly prior to the pandemic. However, the results of this study suggest that those with MDD do not experience a significant worsening in symptoms during the first months of the Covid − 19 pandemic.

Original language	English
Article number	435
Number of pages	1
Journal	BMC Psychiatry
Volume	21
Issue number	1
DOIs	https://doi.org/10.1186/s12888-021-03434-5
Publication status	Published - 1 Sept 2021

Keywords

Major depressive disorder
Mobile health
Remote measurement technology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12888-021-03434-5

Cite this

on behalf of the RADAR-CNS consortium, Leightley, D., Lavelle, G., White, K. M., Sun, S., Matcham, F., Ivan, A., Oetzmann, C., Penninx, B. W. J. H., Lamers, F., Siddi, S., Haro, J. M., Myin-Germeys, I., Bruce, S., Nica, R., Wickersham, A., Annas, P., Mohr, D. C., Simblett, S., ... Hotopf, M. (2021). Investigating the impact of COVID-19 lockdown on adults with a recent history of recurrent major depressive disorder: a multi-Centre study using remote measurement technology. BMC Psychiatry, 21(1), Article 435. https://doi.org/10.1186/s12888-021-03434-5

@article{28ba7fc409774e2980511a7c79ac59b1,

title = "Investigating the impact of COVID-19 lockdown on adults with a recent history of recurrent major depressive disorder: a multi-Centre study using remote measurement technology",

abstract = "Background: The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes a clinical illness Covid-19, has had a major impact on mental health globally. Those diagnosed with major depressive disorder (MDD) may be negatively impacted by the global pandemic due to social isolation, feelings of loneliness or lack of access to care. This study seeks to assess the impact of the 1st lockdown – pre-, during and post – in adults with a recent history of MDD across multiple centres. Methods: This study is a secondary analysis of an on-going cohort study, RADAR-MDD project, a multi-centre study examining the use of remote measurement technology (RMT) in monitoring MDD. Self-reported questionnaire and passive data streams were analysed from participants who had joined the project prior to 1st December 2019 and had completed Patient Health and Self-esteem Questionnaires during the pandemic (n = 252). We used mixed models for repeated measures to estimate trajectories of depressive symptoms, self-esteem, and sleep duration. Results: In our sample of 252 participants, 48% (n = 121) had clinically relevant depressive symptoms shortly before the pandemic. For the sample as a whole, we found no evidence that depressive symptoms or self-esteem changed between pre-, during- and post-lockdown. However, we found evidence that mean sleep duration (in minutes) decreased significantly between during- and post- lockdown (− 12.16; 95% CI − 18.39 to − 5.92; p < 0.001). We also found that those experiencing clinically relevant depressive symptoms shortly before the pandemic showed a decrease in depressive symptoms, self-esteem and sleep duration between pre- and during- lockdown (interaction p = 0.047, p = 0.045 and p < 0.001, respectively) as compared to those who were not. Conclusions: We identified changes in depressive symptoms and sleep duration over the course of lockdown, some of which varied according to whether participants were experiencing clinically relevant depressive symptoms shortly prior to the pandemic. However, the results of this study suggest that those with MDD do not experience a significant worsening in symptoms during the first months of the Covid − 19 pandemic.",

keywords = "Major depressive disorder, Mobile health, Remote measurement technology",

author = "{on behalf of the RADAR-CNS consortium} and Daniel Leightley and Grace Lavelle and White, {Katie M.} and Shaoxiong Sun and Faith Matcham and Alina Ivan and Carolin Oetzmann and Penninx, {Brenda W.J.H.} and Femke Lamers and Sara Siddi and Haro, {Josep Mario} and Inez Myin-Germeys and Stuart Bruce and Raluca Nica and Alice Wickersham and Peter Annas and Mohr, {David C.} and Sara Simblett and Til Wykes and Nicholas Cummins and Folarin, {Amos Akinola} and Pauline Conde and Yatharth Ranjan and Dobson, {Richard J.B.} and Narayan, {Viabhav A.} and Mathew Hotopf",

note = "Funding Information: The RADAR-CNS project ( www.radar-cns.org ) has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115902. This Joint Undertaking receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation programme and EFPIA ( www.imi.europa.eu ). This communication reflects the views of the RADAR-CNS consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The funding body have not been involved in the design of the study, the collection or analysis of data, or the interpretation of data. Funding Information: Participant recruitment in Amsterdam was partially accomplished through Hersenonderzoek.nl, a Dutch online registry that facilitates participant recruitment for neuroscience studies ( https://hersenonderzoek.nl/ ). Hersenonderzoek.nl is funded by ZonMw-Memorabel (project no 73305095003), a project in the context of the Dutch Deltaplan Dementie, Gieskes-Strijbis Foundation, the Alzheimer{\textquoteright}s Society in the Netherlands and Brain Foundation Netherlands. Participants from Spain were recruited from 4 clinical network services: Parc Sanitari Sant Joan de D{\'e}u Network services, Institut Catal{\`a} de la Salut, Institut Pere Mata Hospital Cl{\'i}nico San Carlos. This paper represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre and South London and Maudsley NHS Foundation Trust and King{\textquoteright}s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Funding Information: Participant recruitment in Amsterdam was partially accomplished through Hersenonderzoek.nl, a Dutch online registry that facilitates participant recruitment for neuroscience studies (https://hersenonderzoek.nl/). Hersenonderzoek.nl is funded by ZonMw-Memorabel (project no 73305095003), a project in the context of the Dutch Deltaplan Dementie, Gieskes-Strijbis Foundation, the Alzheimer?s Society in the Netherlands and Brain Foundation Netherlands. Participants from Spain were recruited from 4 clinical network services: Parc Sanitari Sant Joan de D?u Network services, Institut Catal? de la Salut, Institut Pere Mata Hospital Cl?nico San Carlos. This paper represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre and South London and Maudsley NHS Foundation Trust and King?s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Publisher Copyright: {\textcopyright} 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = sep,

day = "1",

doi = "10.1186/s12888-021-03434-5",

language = "English",

volume = "21",

journal = "BMC Psychiatry",

issn = "1471-244X",

publisher = "BioMed Central",

number = "1",

}

on behalf of the RADAR-CNS consortium, Leightley, D, Lavelle, G, White, KM, Sun, S, Matcham, F, Ivan, A, Oetzmann, C, Penninx, BWJH, Lamers, F, Siddi, S, Haro, JM, Myin-Germeys, I, Bruce, S, Nica, R, Wickersham, A, Annas, P, Mohr, DC, Simblett, S, Wykes, T , Cummins, N , Folarin, AA, Conde, P, Ranjan, Y, Dobson, RJB, Narayan, VA & Hotopf, M 2021, 'Investigating the impact of COVID-19 lockdown on adults with a recent history of recurrent major depressive disorder: a multi-Centre study using remote measurement technology', BMC Psychiatry, vol. 21, no. 1, 435. https://doi.org/10.1186/s12888-021-03434-5

Investigating the impact of COVID-19 lockdown on adults with a recent history of recurrent major depressive disorder: a multi-Centre study using remote measurement technology. / on behalf of the RADAR-CNS consortium ; Leightley, Daniel; Lavelle, Grace et al.
In: BMC Psychiatry, Vol. 21, No. 1, 435, 01.09.2021.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Investigating the impact of COVID-19 lockdown on adults with a recent history of recurrent major depressive disorder

T2 - a multi-Centre study using remote measurement technology

AU - on behalf of the RADAR-CNS consortium

AU - Leightley, Daniel

AU - Lavelle, Grace

AU - White, Katie M.

AU - Sun, Shaoxiong

AU - Matcham, Faith

AU - Ivan, Alina

AU - Oetzmann, Carolin

AU - Penninx, Brenda W.J.H.

AU - Lamers, Femke

AU - Siddi, Sara

AU - Haro, Josep Mario

AU - Myin-Germeys, Inez

AU - Bruce, Stuart

AU - Nica, Raluca

AU - Wickersham, Alice

AU - Annas, Peter

AU - Mohr, David C.

AU - Simblett, Sara

AU - Wykes, Til

AU - Cummins, Nicholas

AU - Folarin, Amos Akinola

AU - Conde, Pauline

AU - Ranjan, Yatharth

AU - Dobson, Richard J.B.

AU - Narayan, Viabhav A.

AU - Hotopf, Mathew

N1 - Funding Information: The RADAR-CNS project ( www.radar-cns.org ) has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115902. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA ( www.imi.europa.eu ). This communication reflects the views of the RADAR-CNS consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The funding body have not been involved in the design of the study, the collection or analysis of data, or the interpretation of data. Funding Information: Participant recruitment in Amsterdam was partially accomplished through Hersenonderzoek.nl, a Dutch online registry that facilitates participant recruitment for neuroscience studies ( https://hersenonderzoek.nl/ ). Hersenonderzoek.nl is funded by ZonMw-Memorabel (project no 73305095003), a project in the context of the Dutch Deltaplan Dementie, Gieskes-Strijbis Foundation, the Alzheimer’s Society in the Netherlands and Brain Foundation Netherlands. Participants from Spain were recruited from 4 clinical network services: Parc Sanitari Sant Joan de Déu Network services, Institut Català de la Salut, Institut Pere Mata Hospital Clínico San Carlos. This paper represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre and South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Funding Information: Participant recruitment in Amsterdam was partially accomplished through Hersenonderzoek.nl, a Dutch online registry that facilitates participant recruitment for neuroscience studies (https://hersenonderzoek.nl/). Hersenonderzoek.nl is funded by ZonMw-Memorabel (project no 73305095003), a project in the context of the Dutch Deltaplan Dementie, Gieskes-Strijbis Foundation, the Alzheimer?s Society in the Netherlands and Brain Foundation Netherlands. Participants from Spain were recruited from 4 clinical network services: Parc Sanitari Sant Joan de D?u Network services, Institut Catal? de la Salut, Institut Pere Mata Hospital Cl?nico San Carlos. This paper represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre and South London and Maudsley NHS Foundation Trust and King?s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Publisher Copyright: © 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/9/1

Y1 - 2021/9/1

N2 - Background: The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes a clinical illness Covid-19, has had a major impact on mental health globally. Those diagnosed with major depressive disorder (MDD) may be negatively impacted by the global pandemic due to social isolation, feelings of loneliness or lack of access to care. This study seeks to assess the impact of the 1st lockdown – pre-, during and post – in adults with a recent history of MDD across multiple centres. Methods: This study is a secondary analysis of an on-going cohort study, RADAR-MDD project, a multi-centre study examining the use of remote measurement technology (RMT) in monitoring MDD. Self-reported questionnaire and passive data streams were analysed from participants who had joined the project prior to 1st December 2019 and had completed Patient Health and Self-esteem Questionnaires during the pandemic (n = 252). We used mixed models for repeated measures to estimate trajectories of depressive symptoms, self-esteem, and sleep duration. Results: In our sample of 252 participants, 48% (n = 121) had clinically relevant depressive symptoms shortly before the pandemic. For the sample as a whole, we found no evidence that depressive symptoms or self-esteem changed between pre-, during- and post-lockdown. However, we found evidence that mean sleep duration (in minutes) decreased significantly between during- and post- lockdown (− 12.16; 95% CI − 18.39 to − 5.92; p < 0.001). We also found that those experiencing clinically relevant depressive symptoms shortly before the pandemic showed a decrease in depressive symptoms, self-esteem and sleep duration between pre- and during- lockdown (interaction p = 0.047, p = 0.045 and p < 0.001, respectively) as compared to those who were not. Conclusions: We identified changes in depressive symptoms and sleep duration over the course of lockdown, some of which varied according to whether participants were experiencing clinically relevant depressive symptoms shortly prior to the pandemic. However, the results of this study suggest that those with MDD do not experience a significant worsening in symptoms during the first months of the Covid − 19 pandemic.

AB - Background: The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes a clinical illness Covid-19, has had a major impact on mental health globally. Those diagnosed with major depressive disorder (MDD) may be negatively impacted by the global pandemic due to social isolation, feelings of loneliness or lack of access to care. This study seeks to assess the impact of the 1st lockdown – pre-, during and post – in adults with a recent history of MDD across multiple centres. Methods: This study is a secondary analysis of an on-going cohort study, RADAR-MDD project, a multi-centre study examining the use of remote measurement technology (RMT) in monitoring MDD. Self-reported questionnaire and passive data streams were analysed from participants who had joined the project prior to 1st December 2019 and had completed Patient Health and Self-esteem Questionnaires during the pandemic (n = 252). We used mixed models for repeated measures to estimate trajectories of depressive symptoms, self-esteem, and sleep duration. Results: In our sample of 252 participants, 48% (n = 121) had clinically relevant depressive symptoms shortly before the pandemic. For the sample as a whole, we found no evidence that depressive symptoms or self-esteem changed between pre-, during- and post-lockdown. However, we found evidence that mean sleep duration (in minutes) decreased significantly between during- and post- lockdown (− 12.16; 95% CI − 18.39 to − 5.92; p < 0.001). We also found that those experiencing clinically relevant depressive symptoms shortly before the pandemic showed a decrease in depressive symptoms, self-esteem and sleep duration between pre- and during- lockdown (interaction p = 0.047, p = 0.045 and p < 0.001, respectively) as compared to those who were not. Conclusions: We identified changes in depressive symptoms and sleep duration over the course of lockdown, some of which varied according to whether participants were experiencing clinically relevant depressive symptoms shortly prior to the pandemic. However, the results of this study suggest that those with MDD do not experience a significant worsening in symptoms during the first months of the Covid − 19 pandemic.

KW - Major depressive disorder

KW - Mobile health

KW - Remote measurement technology

UR - http://www.scopus.com/inward/record.url?scp=85114393939&partnerID=8YFLogxK

U2 - 10.1186/s12888-021-03434-5

DO - 10.1186/s12888-021-03434-5

M3 - Article

AN - SCOPUS:85114393939

SN - 1471-244X

VL - 21

JO - BMC Psychiatry

JF - BMC Psychiatry

IS - 1

M1 - 435

ER -

Investigating the impact of COVID-19 lockdown on adults with a recent history of recurrent major depressive disorder: a multi-Centre study using remote measurement technology

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this